vs
MANNATECH INC（MTEX）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是MANNATECH INC的1.0倍（$30.3M vs $29.2M），MANNATECH INC净利率更高（6.6% vs -221.3%，领先227.9%），REGENXBIO Inc.同比增速更快（43.0% vs -8.1%），MANNATECH INC自由现金流更多（$-2.0M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -5.4%）
曼纳泰克是一家公开上市的跨国多层次直销企业，主营膳食补充剂与个人护理产品，由塞缪尔·卡斯特于1993年11月创立，总部位于美国德克萨斯州花丘，股票在纳斯达克挂牌交易。截至2017年，公司共有252名雇员，产品通过约22万名独立销售代理推广销售。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
MTEX vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.0倍
$29.2M
营收增速更快
RGNX
高出51.1%
-8.1%
净利率更高
MTEX
高出227.9%
-221.3%
自由现金流更多
MTEX
多$50.8M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-5.4%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $29.2M | $30.3M |
| 净利润 | $1.9M | $-67.1M |
| 毛利率 | 76.4% | — |
| 营业利润率 | 6.9% | -190.0% |
| 净利率 | 6.6% | -221.3% |
| 营收同比 | -8.1% | 43.0% |
| 净利润同比 | 686.6% | -31.2% |
| 每股收益（稀释后） | $1.01 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MTEXRGNX
| Q4 25 | — | $30.3M | ||
| Q3 25 | $29.2M | $29.7M | ||
| Q2 25 | — | $21.4M | ||
| Q1 25 | $26.6M | $89.0M | ||
| Q4 24 | $29.0M | $21.2M | ||
| Q3 24 | $31.7M | $24.2M | ||
| Q2 24 | $27.7M | $22.3M | ||
| Q1 24 | $29.4M | $15.6M |
净利润MTEXRGNX
| Q4 25 | — | $-67.1M | ||
| Q3 25 | $1.9M | $-61.9M | ||
| Q2 25 | — | $-70.9M | ||
| Q1 25 | $-1.5M | $6.1M | ||
| Q4 24 | $2.3M | $-51.2M | ||
| Q3 24 | $-328.0K | $-59.6M | ||
| Q2 24 | $-624.0K | $-53.0M | ||
| Q1 24 | $1.2M | $-63.3M |
毛利率MTEXRGNX
| Q4 25 | — | — | ||
| Q3 25 | 76.4% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 74.3% | — | ||
| Q4 24 | 80.6% | 70.2% | ||
| Q3 24 | 74.5% | 48.8% | ||
| Q2 24 | 77.1% | 52.5% | ||
| Q1 24 | 78.6% | 72.6% |
营业利润率MTEXRGNX
| Q4 25 | — | -190.0% | ||
| Q3 25 | 6.9% | -176.3% | ||
| Q2 25 | — | -296.3% | ||
| Q1 25 | -3.1% | 13.6% | ||
| Q4 24 | 3.0% | -242.1% | ||
| Q3 24 | 2.8% | -256.6% | ||
| Q2 24 | -4.1% | -251.3% | ||
| Q1 24 | 2.8% | -408.8% |
净利率MTEXRGNX
| Q4 25 | — | -221.3% | ||
| Q3 25 | 6.6% | -208.3% | ||
| Q2 25 | — | -331.8% | ||
| Q1 25 | -5.8% | 6.8% | ||
| Q4 24 | 7.8% | -241.3% | ||
| Q3 24 | -1.0% | -246.3% | ||
| Q2 24 | -2.2% | -237.7% | ||
| Q1 24 | 4.0% | -405.4% |
每股收益（稀释后）MTEXRGNX
| Q4 25 | — | $-1.30 | ||
| Q3 25 | $1.01 | $-1.20 | ||
| Q2 25 | — | $-1.38 | ||
| Q1 25 | $-0.80 | $0.12 | ||
| Q4 24 | $1.19 | $-0.99 | ||
| Q3 24 | $-0.17 | $-1.17 | ||
| Q2 24 | $-0.33 | $-1.05 | ||
| Q1 24 | $0.63 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $7.1M | $230.1M |
| 总债务越低越好 | $2.9M | — |
| 股东权益账面价值 | $7.0M | $102.7M |
| 总资产 | $33.9M | $453.0M |
| 负债/权益比越低杠杆越低 | 0.42× | — |
8季度趋势，按日历期对齐
现金及短期投资MTEXRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | $7.1M | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | $9.3M | $267.9M | ||
| Q4 24 | $11.4M | $234.7M | ||
| Q3 24 | $12.2M | $255.5M | ||
| Q2 24 | $9.2M | $290.4M | ||
| Q1 24 | $7.9M | $338.7M |
总债务MTEXRGNX
| Q4 25 | — | — | ||
| Q3 25 | $2.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益MTEXRGNX
| Q4 25 | — | $102.7M | ||
| Q3 25 | $7.0M | $161.5M | ||
| Q2 25 | — | $213.7M | ||
| Q1 25 | $7.6M | $274.2M | ||
| Q4 24 | $8.6M | $259.7M | ||
| Q3 24 | $10.0M | $301.4M | ||
| Q2 24 | $8.2M | $348.3M | ||
| Q1 24 | $10.4M | $390.7M |
总资产MTEXRGNX
| Q4 25 | — | $453.0M | ||
| Q3 25 | $33.9M | $525.2M | ||
| Q2 25 | — | $581.0M | ||
| Q1 25 | $36.7M | $490.9M | ||
| Q4 24 | $36.1M | $466.0M | ||
| Q3 24 | $40.6M | $519.1M | ||
| Q2 24 | $39.9M | $569.4M | ||
| Q1 24 | $41.1M | $629.2M |
负债/权益比MTEXRGNX
| Q4 25 | — | — | ||
| Q3 25 | 0.42× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.3M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-2.0M | $-52.8M |
| 自由现金流率自由现金流/营收 | -6.8% | -174.0% |
| 资本支出强度资本支出/营收 | 2.4% | 1.7% |
| 现金转化率经营现金流/净利润 | -0.68× | — |
| 过去12个月自由现金流最近4个季度 | $-1.2M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流MTEXRGNX
| Q4 25 | — | $-52.3M | ||
| Q3 25 | $-1.3M | $-56.0M | ||
| Q2 25 | — | $-49.3M | ||
| Q1 25 | $-1.4M | $33.6M | ||
| Q4 24 | $-219.0K | $-31.6M | ||
| Q3 24 | $3.3M | $-40.5M | ||
| Q2 24 | $-2.7M | $-45.5M | ||
| Q1 24 | $1.9M | $-55.5M |
自由现金流MTEXRGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | $-2.0M | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | $-1.9M | $32.6M | ||
| Q4 24 | $-325.0K | $-32.7M | ||
| Q3 24 | $3.0M | $-40.9M | ||
| Q2 24 | $-2.7M | $-46.0M | ||
| Q1 24 | $1.8M | $-56.0M |
自由现金流率MTEXRGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | -6.8% | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | -7.0% | 36.6% | ||
| Q4 24 | -1.1% | -154.2% | ||
| Q3 24 | 9.5% | -168.9% | ||
| Q2 24 | -9.9% | -206.2% | ||
| Q1 24 | 6.2% | -358.5% |
资本支出强度MTEXRGNX
| Q4 25 | — | 1.7% | ||
| Q3 25 | 2.4% | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | 1.8% | 1.2% | ||
| Q4 24 | 0.4% | 5.1% | ||
| Q3 24 | 0.8% | 1.3% | ||
| Q2 24 | 0.3% | 2.1% | ||
| Q1 24 | 0.2% | 3.6% |
现金转化率MTEXRGNX
| Q4 25 | — | — | ||
| Q3 25 | -0.68× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | -0.10× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.59× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MTEX
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
